TY - JOUR
T1 - Exploring the Relationship between Anti-VEGF Therapy and Glaucoma
T2 - Implications for Management Strategies
AU - Daka, Qëndresë
AU - Špegel, Nina
AU - Atanasovska Velkovska, Makedonka
AU - Steblovnik, Tjaša
AU - Kolko, Miriam
AU - Neziri, Burim
AU - Cvenkel, Barbara
PY - 2023/7/14
Y1 - 2023/7/14
N2 - A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.
AB - A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.
UR - http://www.scopus.com/inward/record.url?scp=85166354352&partnerID=8YFLogxK
U2 - 10.3390/jcm12144674
DO - 10.3390/jcm12144674
M3 - Review
C2 - 37510790
SN - 2077-0383
VL - 12
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 14
M1 - 4674
ER -